Cargando…
Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients
To compare the efficacy and safety of umbilical cord blood mononuclear cells (CBMNC) and azathioprine (AZA) in the treatment of patients with steroid-dependent or -resistant ulcerative colitis. One hundred and six patients diagnosed with steroid-dependent or -resistant ulcerative colitis were studie...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871094/ https://www.ncbi.nlm.nih.gov/pubmed/29599923 http://dx.doi.org/10.18632/oncotarget.24541 |
_version_ | 1783309599477071872 |
---|---|
author | Chen, Liang Gao, Yuan Zhang, Zongmei Sun, Mingming Yang, Wenjing Liu, Zhanju Jiang, Xueliang |
author_facet | Chen, Liang Gao, Yuan Zhang, Zongmei Sun, Mingming Yang, Wenjing Liu, Zhanju Jiang, Xueliang |
author_sort | Chen, Liang |
collection | PubMed |
description | To compare the efficacy and safety of umbilical cord blood mononuclear cells (CBMNC) and azathioprine (AZA) in the treatment of patients with steroid-dependent or -resistant ulcerative colitis. One hundred and six patients diagnosed with steroid-dependent or -resistant ulcerative colitis were studied retrospectively, including 36 patients treated with CBMNC and 70 treated with AZA. To reduce confounding bias due to retrospective nature of this study, the propensity score matching system was applied to equipoise the pretreatment data of two groups. After matching, 35 matched pairs (1:1) were created. The ratios of clinical remission, clinical response and endoscopic mucosal healing, Mayo score, and major complications were compared between two groups at weeks 8, 16, and 36 after treatment. The results demonstrated that the ratios of clinical remission (80% vs. 57%, P < 0.05) and mucosal healing (74% vs. 51%, P < 0.05) were significantly higher in CBMNC-treated patients compared with those in AZA-treated patients at week 8. The erythrocyte sedimentation rate was significantly decreased in CBMNC group compared with that in AZA-treated group (14.5 ± 3.9 mm/h vs. 18.0 ± 5.7 mm/h, P < 0.01) at week 8. In AZA group, 2 patients had neutropenia and 3 patients had elevated alanine aminotransferase levels, whereas no obvious side-effects were observed in CBMNC-treated group. Our results reveal that CBMNC therapy appears to be an effective and safe strategy for patients with steroid-dependent or -resistant ulcerative colitis. Further prospective studies are needed to define the potential roles and mechanisms of CBMNC in the treatment of refractory ulcerative colitis. |
format | Online Article Text |
id | pubmed-5871094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58710942018-03-29 Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients Chen, Liang Gao, Yuan Zhang, Zongmei Sun, Mingming Yang, Wenjing Liu, Zhanju Jiang, Xueliang Oncotarget Research Paper To compare the efficacy and safety of umbilical cord blood mononuclear cells (CBMNC) and azathioprine (AZA) in the treatment of patients with steroid-dependent or -resistant ulcerative colitis. One hundred and six patients diagnosed with steroid-dependent or -resistant ulcerative colitis were studied retrospectively, including 36 patients treated with CBMNC and 70 treated with AZA. To reduce confounding bias due to retrospective nature of this study, the propensity score matching system was applied to equipoise the pretreatment data of two groups. After matching, 35 matched pairs (1:1) were created. The ratios of clinical remission, clinical response and endoscopic mucosal healing, Mayo score, and major complications were compared between two groups at weeks 8, 16, and 36 after treatment. The results demonstrated that the ratios of clinical remission (80% vs. 57%, P < 0.05) and mucosal healing (74% vs. 51%, P < 0.05) were significantly higher in CBMNC-treated patients compared with those in AZA-treated patients at week 8. The erythrocyte sedimentation rate was significantly decreased in CBMNC group compared with that in AZA-treated group (14.5 ± 3.9 mm/h vs. 18.0 ± 5.7 mm/h, P < 0.01) at week 8. In AZA group, 2 patients had neutropenia and 3 patients had elevated alanine aminotransferase levels, whereas no obvious side-effects were observed in CBMNC-treated group. Our results reveal that CBMNC therapy appears to be an effective and safe strategy for patients with steroid-dependent or -resistant ulcerative colitis. Further prospective studies are needed to define the potential roles and mechanisms of CBMNC in the treatment of refractory ulcerative colitis. Impact Journals LLC 2018-01-04 /pmc/articles/PMC5871094/ /pubmed/29599923 http://dx.doi.org/10.18632/oncotarget.24541 Text en Copyright: © 2018 Chen et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Chen, Liang Gao, Yuan Zhang, Zongmei Sun, Mingming Yang, Wenjing Liu, Zhanju Jiang, Xueliang Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title | Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title_full | Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title_fullStr | Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title_full_unstemmed | Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title_short | Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
title_sort | umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871094/ https://www.ncbi.nlm.nih.gov/pubmed/29599923 http://dx.doi.org/10.18632/oncotarget.24541 |
work_keys_str_mv | AT chenliang umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT gaoyuan umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT zhangzongmei umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT sunmingming umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT yangwenjing umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT liuzhanju umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients AT jiangxueliang umbilicalcordbloodmononuclearcelltherapyinducesclinicalremissionofsteroiddependentorresistantulcerativecolitispatients |